Home Cart Sign in  
Chemical Structure| 1887095-82-0 Chemical Structure| 1887095-82-0

Structure of RapaLink-1
CAS No.: 1887095-82-0

Chemical Structure| 1887095-82-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RapaLink-1 is the third-generation mTOR inhibitor exploiting the unique juxtaposition of two drug (first- and second-generation mTOR kinase inhibitors) –binding pockets to create a bivalent interaction that allows inhibition of the mutants which has resistance to the previous TORKi (mTOR kinase inhibitors).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RapaLink-1

CAS No. :1887095-82-0
Formula : C91H138N12O24
M.W : 1784.14
SMILES Code : NC1=C2C(C3=CC=C4OC(N)=NC4=C3)=NN(CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN5N=NC(COCCO[C@@H]6CC[C@@H](C[C@@H](C)[C@@]7(CC([C@H](C)/C=C(C)/[C@@H](O)[C@@H](OC)C([C@H](C)C[C@H](C)/C=C/C=C\C=C(C)\[C@@H](OC)C[C@@]8(CC[C@@H](C)[C@@](C(C(N9CCCC[C@]9(C(O7)=O)[H])=O)=O)(O)O8)[H])=O)=O)[H])C[C@H]6OC)=C5)=O)C2=NC=N1
MDL No. :MFCD32633594

Safety of RapaLink-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of RapaLink-1

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
K562 cells 3 nM 24 hours Evaluate the effect of IFITM expression on the intracellular activity of RapaLink-1, results show that IFITM expression promotes the intracellular activity of RapaLink-1 Science. 2022 Dec 9;378(6624):1097-1104
Beta-TC-6 cells 10 nM 24 hours To investigate the effects of RapaLink-1 on amino acid metabolism and mitochondrial functions. Results showed that RapaLink-1 significantly decreased L-aspartate, L-asparagine, L-glutamate, and glycine levels, and reduced ATP production and non-mitochondrial oxygen consumption. Nutrients. 2022 Jul 22;14(15):3022
PC3 cells 0.3 nM 24 hours Chronic low-dose RapaLink1 treatment substantially inhibited mTORC1 activity without affecting mTORC2 activity. Sci Signal. 2021 Sep 21;14(701):eabe0161
Non-cancerous neural stem cells (iNSC) 15.5 nM (IC50) 4 days RL1 showed weaker inhibitory effects on non-cancerous neural stem cells, indicating selectivity for cancer cells. Cancers (Basel). 2020 Dec 21;12(12):3859
Glioblastoma stem cells (GSCs) 1.5, 6, 12, 24, 48 nM 4 days RL1 significantly inhibited cell growth, proliferation, migration, and clonogenic potential of GSCs, and reduced the expression of stem cell markers (CD133, SOX2) and EMT markers (CD44, ZEB1). Cancers (Basel). 2020 Dec 21;12(12):3859
3T3-L1 adipocytes 3 nM, 10 nM and 20 nM 4 hours High-dose RapaLink1 substantially inhibited insulin-induced glucose uptake, indicating a major role for mTORC2, but not mTORC1, in acute insulin-regulated glucose uptake. Sci Signal. 2021 Sep 21;14(701):eabe0161
MCF7 cells 10 nM 4 hours To monitor mTOR signaling by western blot, results showed that RapaLink-1 significantly reduced the levels of phospho-S6 and phospho-4EBP, while the addition of FK506 completely blocked this effect Nature. 2022 Sep;609(7928):822-828
HEK-293E cells 3 nM 4 hours Selectively and almost completely blocked mTORC1 activity toward both rapamycin-sensitive and rapamycin-resistant sites without any demonstrable effect on mTORC2 targets. Sci Signal. 2021 Sep 21;14(701):eabe0161
SU-DHL-6 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
SU-DHL-4 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
SU-DHL-10 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
DoHH2 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
Toledo 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
OCI-LY19 12.5 nM and 50 nM 48 hours Evaluate the sensitivity of RapaLink-1 in EZH2 wild-type and mutant lymphoma cells Sci Transl Med. 2017 Jun 28;9(396):eaak9969
Normal human lung fibroblasts (NHLFs) 2 nM 48 hours RapaLink-1 completely inhibited TGF-β-induced ATF4 accumulation and metabolic reprogramming, including increases in glycolysis and mitochondrial oxygen consumption. Am J Respir Cell Mol Biol. 2020 Nov;63(5):601-612
BM18 PDX organoids 0.0003 µM (IC50) 48 hours To evaluate the cytotoxic effect of RapaLink-1 on BM18 PDX organoids, results showed that RapaLink-1 significantly reduced organoid viability. Front Oncol. 2020 Jun 23;10:1012
LAPC9 PDX organoids 0.0046 µM (IC50) 48 hours To evaluate the cytotoxic effect of RapaLink-1 on LAPC9 PDX organoids, results showed that RapaLink-1 significantly reduced organoid viability. Front Oncol. 2020 Jun 23;10:1012
HeLa cells 1 nM and 3 nM 48 hours RapaLink1 significantly inhibited cell proliferation, showing better efficacy than rapamycin. Sci Signal. 2021 Sep 21;14(701):eabe0161
HMLER cells 5 nM 6 days Inhibition of mTOR signaling, reduction of CD24lowCD44high stem cell population and mammosphere formation Sci Signal. 2019 Feb 26;12(570):eaau8544
K562 cells 10 nM 72 hours To evaluate the effect of RapaLink-1 on cell proliferation, results showed that CRISPRi-mediated knockdown of FKBP12 gene significantly impeded the cellular activity of RapaLink-1 Nature. 2022 Sep;609(7928):822-828

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male mice Alcohol Use Disorder model Intraperitoneal injection 1 mg/kg Three times a week for 4 weeks RapaLink-1 blocked mTORC1 activation in the liver, while RapaBlock protected mTORC1 activity in the periphery. Co-administration of RapaLink-1 and RapaBlock inhibited alcohol-dependent mTORC1 activation in the nucleus accumbens and attenuated alcohol seeking and drinking. Nat Commun. 2021 Jul 27;12(1):4407
BALB/cnu/nu mice Glioblastoma xenograft model Intraperitoneal injection 1 mg/kg RapaLink-1 and 40 mg/kg RapaBlock Every 5 days for 25-30 days To evaluate the therapeutic effect of the combination of RapaLink-1 and RapaBlock, results showed that the combination significantly suppressed tumor growth and improved survival without detectable systemic toxicity Nature. 2022 Sep;609(7928):822-828
NSG mice Orthotopic mammary fat pad implantation model Intraperitoneal injection 1.5 mg/kg Every 5 days for 20 days, then once a week for 2 weeks RapaLink-1 almost completely inhibited tumor formation Sci Signal. 2019 Feb 26;12(570):eaau8544
CB17/SCID mice LAPC9 PDX model Intraperitoneal injection 1.5 mg/kg Every 5-7 days, during the experiment period To evaluate the anti-tumor effect of RapaLink-1 in vivo on LAPC9 PDX model, results showed that RapaLink-1 significantly delayed tumor growth. Front Oncol. 2020 Jun 23;10:1012
Rats Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 2 mg/kg Single dose, 10 minutes after MCAO To investigate the effects of Rapalink-1 on neuronal survival and BBB disruption in the early stage of cerebral ischemia–reperfusion. Results showed that Rapalink-1 increased infarct size and BBB disruption. Front Physiol. 2021 Jul 20;12:706528
Drosophila melanogaster Adult flies Food supplemented 6 μM For three days In contrast to rapamycin, RapaLink1 significantly shortened fly survival under starvation conditions. Sci Signal. 2021 Sep 21;14(701):eabe0161

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.56mL

0.11mL

0.06mL

2.80mL

0.56mL

0.28mL

5.60mL

1.12mL

0.56mL

References

 

Historical Records

Categories